FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022165580> ?p ?o ?g. }

• W2022165580 endingPage "405" @default.
• W2022165580 startingPage "400" @default.
• W2022165580 abstract "Platelet-derived growth factor (PDGF) and its cognate receptor are widely expressed on melanomas. Coexpression of the growth factor and receptor suggests their role in autocrine or paracrine growth mechanisms. Imatinib mesylate was previously reported to have specific activity in inhibiting select tyrosine kinase receptors, including PDGF and c-Kit. Melanoma cells express abundant levels of the PDGF receptor (PDGFR). Nevertheless, c-Kit expression is progressively lost as the cells take on a more highly metastatic phenotype. To investigate the potential of imatinib mesylate as a therapy for melanoma, we studied its effect on the growth of melanoma cells using an in vivo mouse model. Melanoma cells with high malignant potential (PDGFR-positive, c-Kit-negative) or low malignant potential (PDGFR-positive, c-Kit-positive) were injected subcutaneously into athymic nude mice. Mice were treated with imatinib mesylate (100 mg/kg three times weekly) or with phosphate-buffered saline for 4 to 6 wk. PDGFR-alpha and -beta were expressed on all melanoma cell lines tested. The level of PDGFR expression correlated with the metastatic potential of the melanoma cells: higher levels of PDGFR-alpha were expressed on cells with higher metastatic potential, and higher levels of PDGFR-beta were expressed on cells with lower metastatic potential. There was no significant difference in tumor size between treated and control mice. Immunohistochemical studies demonstrated inhibition of PDGFR phosphorylation on the tumors from mice treated with imatinib mesylate but not from control mice, suggesting that the receptors were functional and that the concentration of drug used was appropriate. Our data demonstrated that imatinib mesylate blocked both PDGFR-alpha and PDGFR-beta in vivo. It did not, however, affect the growth of melanoma cells expressing PDGFR, regardless of whether the cells expressed c-Kit." @default.
• W2022165580 created "2016-06-24" @default.
• W2022165580 creator A5001494021 @default.
• W2022165580 creator A5017742334 @default.
• W2022165580 creator A5041289938 @default.
• W2022165580 creator A5074185199 @default.
• W2022165580 creator A5079081497 @default.
• W2022165580 creator A5085792659 @default.
• W2022165580 creator A5087385450 @default.
• W2022165580 creator A5088150372 @default.
• W2022165580 date "2004-02-01" @default.
• W2022165580 modified "2023-10-01" @default.
• W2022165580 title "Imatinib Mesylate Inhibits Platelet-Derived Growth Factor Receptor Phosphorylation of Melanoma Cells But Does Not Affect Tumorigenicity In Vivo" @default.
• W2022165580 cites W1852831326 @default.
• W2022165580 cites W1988698591 @default.
• W2022165580 cites W1996017770 @default.
• W2022165580 cites W1997109671 @default.
• W2022165580 cites W2016086822 @default.
• W2022165580 cites W2030312997 @default.
• W2022165580 cites W2044518419 @default.
• W2022165580 cites W2054846776 @default.
• W2022165580 cites W2067755082 @default.
• W2022165580 cites W2068599501 @default.
• W2022165580 cites W2075108645 @default.
• W2022165580 cites W2079327471 @default.
• W2022165580 cites W2110121929 @default.
• W2022165580 cites W2125772760 @default.
• W2022165580 cites W213656142 @default.
• W2022165580 cites W2168164296 @default.
• W2022165580 cites W2334321795 @default.
• W2022165580 cites W4248663651 @default.
• W2022165580 cites W4321317624 @default.
• W2022165580 doi "https://doi.org/10.1046/j.0022-202x.2004.22231.x" @default.
• W2022165580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15009722" @default.
• W2022165580 hasPublicationYear "2004" @default.
• W2022165580 type Work @default.
• W2022165580 sameAs 2022165580 @default.
• W2022165580 citedByCount "48" @default.
• W2022165580 countsByYear W20221655802012 @default.
• W2022165580 countsByYear W20221655802013 @default.
• W2022165580 countsByYear W20221655802014 @default.
• W2022165580 countsByYear W20221655802015 @default.
• W2022165580 countsByYear W20221655802016 @default.
• W2022165580 countsByYear W20221655802017 @default.
• W2022165580 countsByYear W20221655802018 @default.
• W2022165580 countsByYear W20221655802019 @default.
• W2022165580 countsByYear W20221655802020 @default.
• W2022165580 countsByYear W20221655802021 @default.
• W2022165580 countsByYear W20221655802023 @default.
• W2022165580 crossrefType "journal-article" @default.
• W2022165580 hasAuthorship W2022165580A5001494021 @default.
• W2022165580 hasAuthorship W2022165580A5017742334 @default.
• W2022165580 hasAuthorship W2022165580A5041289938 @default.
• W2022165580 hasAuthorship W2022165580A5074185199 @default.
• W2022165580 hasAuthorship W2022165580A5079081497 @default.
• W2022165580 hasAuthorship W2022165580A5085792659 @default.
• W2022165580 hasAuthorship W2022165580A5087385450 @default.
• W2022165580 hasAuthorship W2022165580A5088150372 @default.
• W2022165580 hasBestOaLocation W20221655801 @default.
• W2022165580 hasConcept C126322002 @default.
• W2022165580 hasConcept C128240485 @default.
• W2022165580 hasConcept C170493617 @default.
• W2022165580 hasConcept C178790620 @default.
• W2022165580 hasConcept C180361614 @default.
• W2022165580 hasConcept C185592680 @default.
• W2022165580 hasConcept C26375932 @default.
• W2022165580 hasConcept C2775960820 @default.
• W2022165580 hasConcept C2777583451 @default.
• W2022165580 hasConcept C2777658100 @default.
• W2022165580 hasConcept C2778729363 @default.
• W2022165580 hasConcept C2780194963 @default.
• W2022165580 hasConcept C2781294074 @default.
• W2022165580 hasConcept C3019892230 @default.
• W2022165580 hasConcept C502942594 @default.
• W2022165580 hasConcept C71924100 @default.
• W2022165580 hasConcept C7876069 @default.
• W2022165580 hasConcept C86803240 @default.
• W2022165580 hasConceptScore W2022165580C126322002 @default.
• W2022165580 hasConceptScore W2022165580C128240485 @default.
• W2022165580 hasConceptScore W2022165580C170493617 @default.
• W2022165580 hasConceptScore W2022165580C178790620 @default.
• W2022165580 hasConceptScore W2022165580C180361614 @default.
• W2022165580 hasConceptScore W2022165580C185592680 @default.
• W2022165580 hasConceptScore W2022165580C26375932 @default.
• W2022165580 hasConceptScore W2022165580C2775960820 @default.
• W2022165580 hasConceptScore W2022165580C2777583451 @default.
• W2022165580 hasConceptScore W2022165580C2777658100 @default.
• W2022165580 hasConceptScore W2022165580C2778729363 @default.
• W2022165580 hasConceptScore W2022165580C2780194963 @default.
• W2022165580 hasConceptScore W2022165580C2781294074 @default.
• W2022165580 hasConceptScore W2022165580C3019892230 @default.
• W2022165580 hasConceptScore W2022165580C502942594 @default.
• W2022165580 hasConceptScore W2022165580C71924100 @default.
• W2022165580 hasConceptScore W2022165580C7876069 @default.
• W2022165580 hasConceptScore W2022165580C86803240 @default.
• W2022165580 hasIssue "2" @default.
• W2022165580 hasLocation W20221655801 @default.
• W2022165580 hasLocation W20221655802 @default.

• next